Articles of Interest [Archive] - Page 2 - HER2 Support Group Forums

Study-Neoadjuvant & PCR (1 replies)
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients (0 replies)
Intimacy Issues after Cancer Tx Not Discussed (0 replies)
Very Interesting Implications for Pathology Results (1 replies)
1960s DDT Exposure Tied to Breast Cancer Risk 50 Years Later (3 replies)
Top 10 Reasons Against Routine Genomic Profiling of Tumors in Patient Care (1 replies)
Also NEJM: The FDA and Genomic Tests — Getting Regulation Right (0 replies)
From the NEJM: Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk (0 replies)
Quantification of HER family receptors in breast cancer (0 replies)
Long-term hazard of recurrence in HER2+ bc patients untreated with anti-Her2 therapy (0 replies)
From the NEJM: Loss of Fingerprints (1 replies)
Encouraging News (3 replies)
Study reveals effective tx for chemobrain (4 replies)
Two New Genes. (2 replies)
Blood pressure medication and cancer patient (0 replies)
Immunotherapy actually works (1 replies)
Using the exposome to predict BC risk (0 replies)
Immune Function Genes Strongly Linked to Outcome of Trastuzumab Trial (0 replies)
Multigene prognostic tests in breast cancer: past, present, future (0 replies)
Markers for the identification of late breast cancer recurrence (0 replies)
Article in The Stranger about a Year with HER2+ BC (1 replies)
New concepts in breast cancer genomics and genetics (0 replies)
Would have been nice to know (left-side radiation) (3 replies)
Outcomes of children exposed in utero to chemotherapy for breast cancer (0 replies)
No Pain, No Gain: A Fallacy So Far (3 replies)
Shorter Canadian radiation at higher dose vs US (0 replies)
Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets (0 replies)
Mistaken Identities Plague Lab Work With Human Cells (1 replies)
http://www.oncologypractice.com/home/article/video-low-recurrence-with-high-her2-expr (0 replies)
Bisphosphonates effective against Her2+ BC (0 replies)
New Drug Combo (0 replies)
Article on WA Univ Breast Cancer Vaccine Trial (0 replies)
NCI funds Univ. of Chicago genomics project (0 replies)
Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resist (1 replies)
How Medical Care Is Being Corrupted (0 replies)
Looking for upcoming Unicorns (miracle treatments) (0 replies)
Coming treatments: Pfizer's Palbociclib (1 replies)
Anyone heard of Blushwood Fruit? (0 replies)
For Anyone Who Has Trouble Swallowing Pills (1 replies)
Methadone as a new cancer treatment drug (7 replies)
METAvivor receives the largest grant in its history (2 replies)
Update on Herceptin Trials (0 replies)
Breast cancer's 'dual citizens' (0 replies)
Research on obesity and bc reveals signaling pathway (0 replies)
Calculating the steeper costs of cancer (0 replies)
The power of the placebo effect (1 replies)
Immune approaches to the treatment of breast cancer, around the corner? (0 replies)
3D-Prints Skin For Breast Cancer Survivors (0 replies)
CLEOPATRA Trial Changes Standard Therapy for Metastatic HER2 Positive Breast Cancer (0 replies)
NJEM correspondence on SOFT Trial (Her2+ related) (0 replies)
Bevacizumab Improves Survival in Metastatic Breast Cancer (0 replies)
Threats to Cancer Care (0 replies)
Immune approaches to the treatment of breast cancer, around the corner? (0 replies)
New Therapy Seeks to Mature Rather Than Kill Cancer Cells (0 replies)
Training Dogs to Sniff Out Cancer (1 replies)
Immune approaches to the treatment of breast cancer, around the corner? (0 replies)
Novel vaccine cuts recurrence in HER2 positive breast cancer patients (0 replies)
Molecular effects of lapatinib in patients with HER2+ DCIS (0 replies)
Quest for Targeted Therapeutic 'Cocktails' Hits Roadblocks (2 replies)
When Patients Read What Their Doctors Write (0 replies)
Don’t judge every tumor by its tissue, scientists say (1 replies)
New Discovery Opens the Door to Possible Cure for Heart Disease (0 replies)
Adding Lapatinib to Trastuzumab Does Not Lengthen the Lives of Women with HER2+ (0 replies)
Researchers Find Gene Signature Predictive of Late Distant Recurrence (2 replies)
Metformin-Promising News In A Non-Conclusive Area (0 replies)
High recurrence risk small HER2+ cancers (0 replies)
Commentary on Study about Cancer Center Advertising (0 replies)
For cancer patients, new tool predicts financial pain (0 replies)
BreastCancer.org tips on Post-Traumatic Stress Disorder (PTSD) (0 replies)
Preventing early menopause in ER negative breast cancer (0 replies)
New Discoveries in Cancer and Heart Disease (3 replies)
Insurers push back against growing cost of cancer treatments (0 replies)
overcoming resistance with HER2 targeted breast and gastric cancer treatments (0 replies)
$2.5M Grant To Solve Mystery of Cancer (Cold Spring Harbor) (0 replies)
Construction and evaluation of a novel humanized HER2-specific chimeric (1 replies)
Biotech Makes Personalized Cancer Vaccines Using Tumor Samples (0 replies)
Vaccine Boosters Reduce Recurrence of Breast Cancer (8 replies)
Prognosis of metachronous contralateral breast cancer (1 replies)
Tumor stage affects risk and prognosis of contralateral breast cancer (0 replies)
KRAS-variant associated with breast, ovarian cancer risk (0 replies)
Has anyone in the UK taken the Pam50 and opted out of chemo?? (0 replies)
Generex Announces Presentation of Primary Efficacy Data & Immunological Response from (1 replies)
Breast Cancer Survival Defined by the ER/PR/HER2 (1 replies)
Phosphorylated p-70S6K Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer (4 replies)
herb-drug interference in human breast cancer cells treated with tamoxifen and trastu (1 replies)
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin) (1 replies)
ER PR Her2 Ki67 & Tamoxifen (0 replies)
Against Metastasis: Brunhilde Felding-Habermann (0 replies)
Tamoxifen Mechanism (5 replies)
Raloxifene and the Prevention of Osteoporosis (1 replies)
Estrogen Replacement in Menopause. NCI (1 replies)
Need for better SERMs. NCI (1 replies)
Tamoxifen and Breast Cancer Prevention. NCI (1 replies)
Estrogen Receptor-Negative Breast Cancer. NCI (0 replies)
Aromatase Inhibitors. National Cancer Institute (0 replies)
Antiestrogens. National Cancer Institute (3 replies)
Estrogen and Cancer. National Cancer Institute (4 replies)
What are Estrogens? National Cancer Institute information (5 replies)
Who is Cold Spring Harbor Laboratory? (8 replies)
DNA The secret of Life (4 replies)
Phase 2 study in neoadjuvant, HER2 3+ Breast Cancer Patients to commence in 2014 (0 replies)
When "HRT" may differ in effects (0 replies)
Aromatase Inhibition and Cognitive Function in Breast Cancer (1 replies)
Circulating nucleic acids as biomarkers in breast cancer (0 replies)
Immunological Research: A multi-faceted approach to curing disease (8 replies)
From the NEJM: Comparative Effectiveness Questions in Oncology (1 replies)
Intermittent Lapatinib Hits Roadblock in HER2 Breast Cancer Study (0 replies)
Pablociclib New Drug (0 replies)
From the NEJM: Hazards of Hindsight — Monitoring the Safety of Nutritional Supplement (0 replies)
Herceptin works with immune cells to downregulate cancer cells (0 replies)
Post-meno hormone tx and effects on bc risk (0 replies)
Could This Be The End Of Cancer? (0 replies)
Diversity improves scientific papers (0 replies)
Epigenetics (3 replies)
Health law concerns for cancer centers (0 replies)
Whole genome sequencing; not ready for prime time (3 replies)
Cooling Cap trial in Los Angeles, CA (0 replies)
Palliative Chemo Can Make It More Likely You'll Die In The ICU (0 replies)
Fighting fire's GP2 info request (3 replies)
Cancer, from the 100 Most Important Science Ideas (0 replies)
NeuVax Patent in Australia (0 replies)
The Downside To Clinical Trials (16 replies)
The genomic map of breast cancer: which roads lead to better targeted therapies? (0 replies)
Blocking metabolic pathways eradicates Acute Leukemia (in Mice) (0 replies)
We have a title: e-Patient (0 replies)
Smoking and Estrogen in Breast Cancer (0 replies)
Pertuzumab (3 replies)
The sequential use of endocrine treatment for advanced breast cancer: where are we? (0 replies)
Understanding vaccines E75/AE37 (3 replies)
Mekinist (Trametinib) a MEK Kinase inhibitor (6 replies)
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four (0 replies)
No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide (3 replies)
Delivery of gene silencing agents for breast cancer therapy (1 replies)
Rads and the myth of chemo wiping out that "last stray cancer cell" (11 replies)
ultra-deep targeted sequencing for personalized bc care (1 replies)
The mind, inflammation, and epigenetics (5 replies)
Cancer Drug Costs (4 replies)
Breast Reconstruction After Radiation (7 replies)
Exemestane may have benefits beyond those of an AI (0 replies)
What Does Cancer Smell Like? (2 replies)
Test Shown to Reduce Early Cancer Deaths is Now Available to Patients (4 replies)
Flax Oil and Herceptin (1 replies)
When a friend is sick (0 replies)
Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells (0 replies)
Mammographic density and risk of breast cancer by age and tumor characteristics. (0 replies)
Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy (0 replies)
Quantitative assessment Ki-67 score for prediction (0 replies)
Beautiful tattoos for reconstructed breasts (0 replies)
Status of AE37 vaccine (0 replies)
NeuVax™ (nelipepimut-S) (1 replies)
10 year Herceptin statistics, for inquiring minds (0 replies)
Suspension of ponatinib marketing & sales (0 replies)
Obesity changes in fat stem cells mediate tumor growth via ER stimulation (0 replies)
What Should HER2/Neu Breast Cancer Patients And Survivors Eat? Food for Breast Cancer (0 replies)
Understanding Perjeta & Perjeta with Herceptin (0 replies)
Unicorn search: MM-302 is a HER2-targeted nanotherapeutic (0 replies)
targeting of erbB3 with MM-121/SAR256212 enhances paclitaxel (3 replies)
The challenge of reporting dense breasts (1 replies)
Pubertal high fat diet: effects on mammary cancer (0 replies)
Pattern of recurrence of early bc differs by intrinsic subtype & proliferation index (24 replies)
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resista (9 replies)
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimen (0 replies)
AMG 900, pan-Aurora kinase inhibitor (0 replies)
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor (0 replies)
Role of Viruses Among 19 Cancers (0 replies)
Clinical Trials Continue Only at a Crawl (0 replies)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the grow (1 replies)
Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of (0 replies)
How to Get into the Brain (0 replies)
Why Oncologists Don’t Like In Vitro Chemosensitivity Tests (4 replies)
Functional profiling article 10/8/13 in NewsMedical (2 replies)
Oligometastases . . . since Cool Breese introduced this term . . . (1 replies)
About 75% of NIH's employees -- or about 14,700 people -- have been furloughed (0 replies)
Angiogenesis in Breast Cancer (12 replies)
Chargers Partner with Breast Cancer Org for Free Mammograms (1 replies)
How Molecular Profiling Works (9 replies)
HER2-positive tumors with mutations in PIK3CA . . . (0 replies)
Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer (0 replies)
Definitions of Stage IV vs. Metastatic Breast Cancer (0 replies)
Questions about Valley breast cancer charity, where donation money is really used (0 replies)
George W. Sledge, Jr., MD (0 replies)
Larry Norton, MD (0 replies)
Hyman B. Muss, MD (0 replies)
Matthew J. Ellis, MD, PhD (0 replies)
H. Shelton Earp, MD (0 replies)
Mitch Dowsett, PhD, BSc (0 replies)
Angelo Di Leo, MD, PhD (0 replies)
Nancy E. Davidson, MD (0 replies)
Andrew Dannenberg, MD (0 replies)
José Baselga, MD, PhD (0 replies)
In cancer drug battle, both sides appeal to ethics (0 replies)
HER2 overexpression renders human breast cancers sensitive to PARP inhibition (10 replies)
Review article of inflammation related breast cancer progression (0 replies)
Study of late vs. early relapse in ER+ breast cancer (1 replies)
New study on acquired Lapatinib resistance (0 replies)
Tykerb? Better with Herceptin for MBC (2 replies)
Targeted Vs Chemo - and targeted wins! (12 replies)
20% decrease in Cancer death (0 replies)
The Annual Report to the Nation on the Status of Cancer, 1975-2009 (0 replies)
A genome-wide association study of chemotherapy-induced alopecia in bc (1 replies)
Message re: Free my genes (0 replies)
European subcutaneous trastuzumab (0 replies)
“Good” Patients and “Difficult” Patients — Rethinking Our Definitions (1 replies)
Her2 treatment crossing over to the Triple Negatives (0 replies)
Researchers uncover details behind breast cancer growth (0 replies)
Exploiting the Metabolic Demands of Senescent Cancer Cells (0 replies)
Ductal Carcinoma In Situ of the Breast: ‘Making the Punishment Fit the Crime’ (1 replies)
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer (0 replies)
Is Soluble Her2 the same as Serum Her2? anyone know? (0 replies)
Pertuzumab Granted Priority Review for Neoadjuvant HER2-Positive Breast Cancer (0 replies)
Patterns of Recurrence Differ by Breast Cancer Node-Negative Subtype (1 replies)
Cancer Prehabilitation: An Opportunity to Decrease Treatment-Related Morbidity (0 replies)
Functional Profiling Leads to Identification of Accurate Genomic Findings (5 replies)
New Cancer Trials focus on modifying patient's own T-Cells (2 replies)
Cancer Prevention Study 3 (0 replies)
Changing perspectives about choosing treatment (1 replies)
Personalized Medicine Gives Rise to New Ethical Questions (0 replies)
A look from the financial sector on upcoming treatments - including 3Ns (0 replies)
General Information About Breast Cancer (2 replies)
Toward Patient-Centered Drug Development in Oncology (2 replies)
Knowing How to Be - Charles A. Moss, MD (0 replies)
Breast cancer risk can be predicted using new technique (0 replies)
My Left Breast, a blog by Heather Millar (0 replies)
Mindfulness and Cancer By Richard C. Frank, MD (0 replies)
The Blood-Brain Barrier and Neuroinflammation - Dr. Datis Kharrazian (10 replies)
"I listen with love to my body's messages" Louise L. Hay (0 replies)
Unique treatment for early stage breast cancer (0 replies)
9 million smokers should get yearly lung screening (0 replies)
Scientists: When diagnosing, rethink the word 'cancer' (0 replies)
UCLA Researchers Find Link Between Intestinal Bacteria and White Blood Cell Cancer (0 replies)
Dr. Finn on the Inhibition of CDK 4/6 in Breast Cancer (0 replies)
Par For the Cure: Dr. Dennis Slamon (0 replies)
Dr.Lorraine Day (0 replies)
Cancer Cure | Turmeric | Natural Cancer Cure (0 replies)
Treating Cancer with Bicarbonate Of Soda! Baking soda (0 replies)
Visual - How does Herceptin Work? (0 replies)
The Breast Cancer Reconstruction Blog (0 replies)
You can heal your life (1 replies)
70% of U.S. plastic surgeons use fat grafting techniques for breast reconstruction (0 replies)
The Brain's Immune System (4 replies)
Gut on Fire Equals Brain on Fire (3 replies)
Afatinib, a targeted therapy that might crossover from lung cancer to Her2+ breast (1 replies)
Neoadjuvant laptinib (Tykerb) and trastuzumab (Herceptin) (0 replies)
Cold caps tested to prevent hair loss during chemo (0 replies)
From Her-2 The Making of Herceptin, a Revolutionary Treatment for Breast Cancer (2 replies)
Dennis Slamon: Anthracycline Not Needed with Trastuzumab; Nonanthracycline-based Regi (0 replies)
Alternatives to preventing cancer Dr. Brownstein (0 replies)
Anti-HER2 Mechanisms of Approved HER2 Inhibitors (0 replies)
Prognostication in Breast Cancer: Are We Smarter Yet? (0 replies)
Her2 Dimerization, a refresher of oncogenic signaling (2 replies)